サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：カルシウムチャネルブロッカー市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年
市場調査レポート
商品コード
1301438

カルシウムチャネルブロッカー市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年

Calcium Channel Blockers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 185 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
カルシウムチャネルブロッカー市場：世界の業界分析、規模、シェア、成長、動向、予測、2023年から2031年
出版日: 2023年05月22日
発行: Transparency Market Research
ページ情報: 英文 185 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

カルシウムチャネルブロッカー市場- レポートの範囲

世界のカルシウムチャネルブロッカー市場に関するTMRの調査レポートは、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も掲載しています。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、カルシウムチャネルブロッカー市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書を参照することが含まれます。

このレポートは、世界のカルシウムチャネルブロッカー市場の競合情勢を詳しく掘り下げています。世界のカルシウムチャネルブロッカー市場で活動している主要プレーヤーが特定され、これらはさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のカルシウムチャネルブロッカー市場のプレーヤーの属性です。

目次

第1章 序文

第2章 仮定と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 主要な洞察

  • 世界における疾病の有病率と罹患率、主要国について
  • 主要製品/ブランド分析
  • パイプライン分析
  • COVID-19のパンデミックが業界に与える影響

第6章 世界市場の分析と予測：医薬品クラス別

  • イントロダクションと定義
  • 主な発見と開発
  • 市場金額予測：医薬品クラス別、2017-2031
    • フェニルアルキルアミン
    • ベンゾチゼピン
    • ジヒドロピリジン
      • 初代
      • 第2世代
      • 第3世代
  • 市場魅力分析：医薬品クラス別

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な発見と開発
  • 市場金額予測：用途別、2017-2031
    • 高血圧
    • 狭心症
    • 不整脈
    • 肥大型心筋症
    • その他（レイノー病など）
  • 市場魅力分析：用途別

第8章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な発見と開発
  • 市場金額予測：投与経路別、2017-2031
    • 経口
    • 非経口
  • 市場魅力分析：投与経路別

第9章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な発見と開発
  • 市場金額予測：流通チャネル別、2017-2031
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力分析：流通チャネル別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場企業- 競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別、2022年
  • 企業プロファイル
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Company, Inc.
    • Novartis AG
    • AstraZeneca
    • Merck &Co. Inc.
    • GSK plc
    • Bayer AG
    • Sun Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited
図表

List of Tables

  • Table 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 05. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 07. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 10. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 11. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 12. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 17. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 20. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 22. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 23. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 25. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 26. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 27. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 28. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 29. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 30. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01. Global Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02. Global Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03. Global Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 04. Global Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 05. Global Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 06. Global Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 07. Global Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 08. Global Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 09. Global Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 10. Global Calcium Channel Blockers Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 11. Global Calcium Channel Blockers Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 12. North America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 13. North America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 14. North America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 15. North America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 16. North America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 17. North America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 18. North America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 19. North America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 20. North America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 21. North America Calcium Channel Blockers Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 22. North America Calcium Channel Blockers Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 23. Europe Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 24. Europe Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 25. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 26. Europe Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 27. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 28. Europe Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 29. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 30. Europe Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 31. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 32. Europe Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 33. Europe Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 34. Asia Pacific Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 35. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 36. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 37. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 38. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 39. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 40. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 41. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 42. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 43. Asia Pacific Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 44. Asia Pacific Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 45. Latin America Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 46. Latin America Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 47. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 48. Latin America Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 49. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 50. Latin America Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 51. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 52. Latin America Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 53. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54. Latin America Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 55. Latin America Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56. Middle East & Africa Calcium Channel Blockers Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 57. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 58. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Drug Class, 2023-2031
  • Figure 59. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Application, 2022 and 2031
  • Figure 60. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 61. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 62. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 63. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 64. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 65. Middle East & Africa Calcium Channel Blockers Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 66. Middle East & Africa Calcium Channel Blockers Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 67. Global Calcium Channel Blockers Market Share Analysis, by Company, 2022
目次
Product Code: TMRGL35687

Calcium Channel Blockers Market - Scope of Report

TMR's report on the global Calcium Channel Blockers market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Calcium Channel Blockers market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Calcium Channel Blockers market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Calcium Channel Blockers market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Calcium Channel Blockers market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Calcium Channel Blockers market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Calcium Channel Blockers market.

The report delves into the competitive landscape of the global Calcium Channel Blockers market. Key players operating in the global Calcium Channel Blockers market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Calcium Channel Blockers market profiled in this report.

Key Questions Answered in Global Calcium Channel Blockers Market Report:

  • What is the sales/revenue generated by Calcium Channel Blockers across all regions during the forecast period?
  • What are the opportunities in the global Calcium Channel Blockers market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Calcium Channel Blockers Market - Research Objectives and Research Approach

The comprehensive report on the global Calcium Channel Blockers market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Calcium Channel Blockers market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Calcium Channel Blockers market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Calcium Channel Blockers Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Calcium Channel Blockers Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries
  • 5.2. Key product/brand Analysis
  • 5.3. Pipeline Analysis
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Calcium Channel Blockers Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Phenylalkylamine
    • 6.3.2. Benzothizepine
    • 6.3.3. Dihydropyridine
      • 6.3.3.1. 1st Generation
      • 6.3.3.2. 2nd Generation
      • 6.3.3.3. 3rd Generation
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Calcium Channel Blockers Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Hypertension
    • 7.3.2. Angina
    • 7.3.3. Arrhythmia
    • 7.3.4. Hypertrophic Cardiomyopathy
    • 7.3.5. Others (Raynaud's disease, etc.)
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Calcium Channel Blockers Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Calcium Channel Blockers Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Calcium Channel Blockers Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Calcium Channel Blockers Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Phenylalkylamine
    • 11.2.2. Benzothizepine
    • 11.2.3. Dihydropyridine
      • 11.2.3.1. 1st Generation
      • 11.2.3.2. 2nd Generation
      • 11.2.3.3. 3rd Generation
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Hypertension
    • 11.3.2. Angina
    • 11.3.3. Arrhythmia
    • 11.3.4. Hypertrophic Cardiomyopathy
    • 11.3.5. Others (Raynaud's disease, etc.)
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Parenteral
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Application
    • 11.7.3. By Route of Administration
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Calcium Channel Blockers Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Phenylalkylamine
    • 12.2.2. Benzothizepine
    • 12.2.3. Dihydropyridine
      • 12.2.3.1. 1st Generation
      • 12.2.3.2. 2nd Generation
      • 12.2.3.3. 3rd Generation
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Hypertension
    • 12.3.2. Angina
    • 12.3.3. Arrhythmia
    • 12.3.4. Hypertrophic Cardiomyopathy
    • 12.3.5. Others (Raynaud's disease, etc.)
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Parenteral
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Application
    • 12.7.3. By Route of Administration
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Calcium Channel Blockers Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Phenylalkylamine
    • 13.2.2. Benzothizepine
    • 13.2.3. Dihydropyridine
      • 13.2.3.1. 1st Generation
      • 13.2.3.2. 2nd Generation
      • 13.2.3.3. 3rd Generation
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Hypertension
    • 13.3.2. Angina
    • 13.3.3. Arrhythmia
    • 13.3.4. Hypertrophic Cardiomyopathy
    • 13.3.5. Others (Raynaud's disease, etc.)
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Parenteral
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Application
    • 13.7.3. By Route of Administration
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Calcium Channel Blockers Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Phenylalkylamine
    • 14.2.2. Benzothizepine
    • 14.2.3. Dihydropyridine
      • 14.2.3.1. 1st Generation
      • 14.2.3.2. 2nd Generation
      • 14.2.3.3. 3rd Generation
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Hypertension
    • 14.3.2. Angina
    • 14.3.3. Arrhythmia
    • 14.3.4. Hypertrophic Cardiomyopathy
    • 14.3.5. Others (Raynaud's disease, etc.)
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Parenteral
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Application
    • 14.7.3. By Route of Administration
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Calcium Channel Blockers Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Phenylalkylamine
    • 15.2.2. Benzothizepine
    • 15.2.3. Dihydropyridine
      • 15.2.3.1. 1st Generation
      • 15.2.3.2. 2nd Generation
      • 15.2.3.3. 3rd Generation
  • 15.3. Market Value Forecast, by Application, 2017-2031
    • 15.3.1. Hypertension
    • 15.3.2. Angina
    • 15.3.3. Arrhythmia
    • 15.3.4. Hypertrophic Cardiomyopathy
    • 15.3.5. Others (Raynaud's disease, etc.)
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.4.1. Oral
    • 15.4.2. Parenteral
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Application
    • 15.7.3. By Route of Administration
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Pfizer, Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Bausch Health Company, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Novartis AG
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. AstraZeneca
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co. Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. GSK plc
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Bayer AG
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sun Pharmaceutical Industries Ltd.
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Daiichi Sankyo Company, Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview